Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Co-activators and Co-repressors02:04

Co-activators and Co-repressors

8.6K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.6K
tRNA Activation02:26

tRNA Activation

22.9K
Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
22.9K
Activation Energy01:26

Activation Energy

86.6K
Activation energy is the minimum amount of energy necessary for a chemical reaction to move forward. The higher the activation energy, the slower the rate of the reaction. However, adding heat to the reaction will increase the rate, since it causes molecules to move faster and increase the likelihood that molecules will collide. The collision and breaking of bonds represents the uphill phase of a reaction and generates the transition state. The transition state is an unstable high-energy state...
86.6K
Eukaryotic Transcription Activators02:42

Eukaryotic Transcription Activators

12.8K
Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
12.8K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

587
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
587
Secondary Active Transport01:55

Secondary Active Transport

137.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
137.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The KRAS, ATR and CHEK1 expression levels in endometrial cancer are the risk factors predicting recurrence.

PloS one·2024
Same author

Comparative Analysis of the Embryonal Brain Tumors Based on Their Molecular Features.

Discovery medicine·2023
Same author

STK4 protein expression pattern follows different trends in endometrioid and serous endometrial adenocarcinoma upon tumor progression.

Scientific reports·2022
Same author

Upregulation of PKN1 as a Prognosis Biomarker for Endometrial Cancer.

Cancer control : journal of the Moffitt Cancer Center·2022
Same author

A Comparative Study on the Viability of Normal and Cancerous Cells upon Irradiation with a Steady Beam of THz Rays.

Life (Basel, Switzerland)·2022
Same author

CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cells.

Neoplasma·2021

Related Experiment Video

Updated: Jan 31, 2026

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K

SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?

Inna Gordiienko1, Larysa Shlapatska1, Larysa Kovalevska1

  • 1Department of Molecular and Cellular Pathobiology, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine, Kyiv, Ukraine.

Clinical Immunology (Orlando, Fla.)
|January 9, 2019
PubMed
Summary

Signaling Lymphocyte Activation Molecule Family member 1 (SLAMF1/CD150) shows varied expression in blood cancers, indicating its potential as a diagnostic marker and therapeutic target for hematologic malignancies.

Keywords:
Chronic lymphocytic leukemiaHematologic malignanciesHematopoietic cellsHodgkin's lymphomaSLAMF1/CD150

More Related Videos

Presynaptically Silent Synapses Studied with Light Microscopy
11:02

Presynaptically Silent Synapses Studied with Light Microscopy

Published on: January 4, 2010

11.9K
Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1
07:42

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1

Published on: February 28, 2025

938

Related Experiment Videos

Last Updated: Jan 31, 2026

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K
Presynaptically Silent Synapses Studied with Light Microscopy
11:02

Presynaptically Silent Synapses Studied with Light Microscopy

Published on: January 4, 2010

11.9K
Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1
07:42

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1

Published on: February 28, 2025

938

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Signaling Lymphocyte Activation Molecule Family (SLAMF) receptors are crucial cell-surface proteins.
  • SLAMF1, also known as CD150, is a key member of this family, primarily expressed in the hematopoietic system.
  • Its expression pattern varies significantly across different hematologic malignancies.

Purpose of the Study:

  • To review the role of SLAMF1/CD150 in the pathogenesis of hematologic malignancies.
  • To highlight CD150's potential as a diagnostic and prognostic marker.
  • To explore CD150 as a therapeutic target in cancer treatment.

Main Methods:

  • Literature review of studies investigating SLAMF1/CD150 expression and function in hematologic malignancies.
  • Analysis of differential CD150 expression patterns in various blood cancers.
  • Evaluation of CD150's involvement in malignant cell fate and tumor microenvironment.

Main Results:

  • CD150 expression is restricted in certain hematologic malignancies, including lymphomas and leukemia.
  • Differential expression suggests CD150's utility as a diagnostic and prognostic indicator.
  • SLAMF1/CD150 influences malignant cell behavior and the tumor microenvironment.

Conclusions:

  • SLAMF1/CD150 plays a significant role in the development of hematologic malignancies.
  • CD150 represents a promising target for novel antibody-based and oncolytic therapies.
  • Further research into CD150's function can lead to improved diagnostic and therapeutic strategies for blood cancers.